Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

September 1, 2022 updated by: Xiaorong Dong, Wuhan Union Hospital, China

An Exploratory Clinical Study of Short Course Radiotherapy Combined With Surufatinib and Sintilimab in the Treatment of Relapsed and Refractory Advanced Solid Tumors

An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

36

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hubei
      • Wuhan, Hubei, China, 430000
        • Union Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 18-75 years (including 18 and 75 years), both genders;
  2. Unresectable malignant tumors confirmed by histology or cytology (mainly biliary tract tumors, gastric cancer, small cell lung cancer, and other tumor types were included as appropriate), which failed at least after first-line standard treatment;
  3. The lesions can be clearly evaluated by imaging;
  4. Expected survival ≥ 12 weeks;
  5. No serious abnormalities of blood system, heart, lung, liver, kidney function or immune deficiency;
  6. Laboratory tests (without blood transfusion within 14 days) shall meet the following requirements:
  7. If a fertile man or woman is willing to use contraception during the trial;
  8. Physical status score ECOG 0-1;
  9. Patients or their family members agreed to participate in the study and signed the informed consent form;

Exclusion Criteria:

  1. Previous treatment with anti-VEGF/VEGFR-targeted drugs, such as surufatinib; Or previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another stimulatory or synergistic inhibition of T-cell receptors (including but not limited to CTLA-4, OX-40, LAG-3, CD137, etc.);
  2. Women who are breast feeding, pregnant or preparing to become pregnant;
  3. Corticosteroids (dose equivalent to prednisone & GT; 10 mg/ day) or other immunosuppressive therapy;
  4. Active, known or suspected autoimmune diseases or before 2 years of the history of the disease (in nearly 2 years can be treated as system of vitiligo, psoriasis, hair loss, or graves disease, need only thyroid hormone replacement therapy for hypothyroidism and only need insulin replacement therapy in patients with type 1 diabetes can group);
  5. Allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation; Persons with HIV infection or active hepatitis b or c (active hepatitis b reference: HBV DNA≥1×104 copies /ml or ≥2000IU/ml; Active hepatitis C reference: HCV RNA≥1×103 copies /ml);
  6. Interstitial lung disease (including past history and current condition), such as interstitial pneumonia, pulmonary fibrosis, or evidence of ILD on baseline chest CT or MRI;
  7. Allergic constitution and multiple drug allergy;
  8. Patients judged by other investigators to be unable to tolerate chemotherapy or not suitable for inclusion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Surufatinib Combined With Sintilimab and SCRT
Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle
Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
5Gy*5F short course radiotherapy will be delivered

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-free Survival (PFS)
Time Frame: From Baseline to primary completion date, about 24 months
A duration from the date of initial treatment to disease progression or death of any cause
From Baseline to primary completion date, about 24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response rate (ORR)
Time Frame: From Baseline to primary completion date, about 24 months
The incidence of confirmed complete response or partial response
From Baseline to primary completion date, about 24 months
Disease Control Rate
Time Frame: From Baseline to primary completion date, about 24 months
The incidence of complete response, partial response and stable disease
From Baseline to primary completion date, about 24 months
Overall survival (OS)
Time Frame: From the time of enrollment to death caused by any reason
From Baseline to primary completion date, about 24 months
From the time of enrollment to death caused by any reason
The incidence of adverse events
Time Frame: From Baseline to primary completion date, about 24 months
The safety and tolerability of Surufatinib will be evaluated based on adverse events data
From Baseline to primary completion date, about 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

September 30, 2022

Primary Completion (ANTICIPATED)

September 30, 2024

Study Completion (ANTICIPATED)

September 30, 2025

Study Registration Dates

First Submitted

September 1, 2022

First Submitted That Met QC Criteria

September 1, 2022

First Posted (ACTUAL)

September 6, 2022

Study Record Updates

Last Update Posted (ACTUAL)

September 6, 2022

Last Update Submitted That Met QC Criteria

September 1, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe